KKR Launches 5M Share Secondary Offering in BridgeBio, Company Gets No Proceeds
BBIO sits 68% above its 52-week low of $46.81 on light trading volume (0.4× avg).
Summary
KKR Genetic Disorder L.P. is selling 5 million shares of BridgeBio in a secondary offering, with the company receiving no proceeds. The sale comes just weeks after BridgeBio raised $934 million in preferred equity and filed a $500 million ATM, signaling continued capital activity. The offering is being led by William Blair, Goldman Sachs, and KKR, and is subject to market conditions. This follows the S-3ASR shelf filed on July 24, 2026, and adds selling pressure from a major existing shareholder.
At the time of this announcement, BBIO was trading at $78.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.9B. The 52-week trading range was $46.81 to $93.42. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.